Literature DB >> 10485250

Discordant and anomalous results among cytotoxicity assays: the confounding properties of eosinophil granule major basic protein on cell viability assays.

H Kubo1, D A Loegering, Y Tohda, J Bankers-Fulbright, C R Weiler, H Nakajima, L L Thomas, C R Adolphson, G J Gleich.   

Abstract

When five cytotoxicity methods compared the toxicity of eosinophil granule major basic protein (MBP) and melittin to K562 and HL-60 cells, strikingly discrepant results were noted. Trypan blue staining, propidium iodide/CellTrackerGreen staining and incorporation of 14C-leucine assays indicated MBP damages > 75% of cells by 1 h. In contrast, 51Cr and lactic dehydrogenase (LDH) release assays indicated MBP damages most cells only at 20 h. All methods indicated melittin damages nearly all cells by 1 h. Further studies showed that without cell transfer, dye staining methods indicated MBP produces < 10% cytotoxicity after 4 h. A modified 14C-leucine assay, employing sodium dodecyl sulfate solubilization and trichloroacetic acid precipitation, showed lower cytotoxicity, 48%, at 4 h. Modified 51Cr and LDH assays showed increased cytotoxicities at 4 h, 34% and 58%, respectively. Overall, MBP's ability to cause molecular and cellular adhesion systematically confounds standard cytotoxicity measurements. However, the modified 14C-leucine assay provides a valid measure of MBP's cytotoxicity and may be useful for analyses of 'sticky' cytotoxins.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10485250     DOI: 10.1016/s0022-1759(99)00055-1

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  2 in total

1.  Eosinophil granule-derived major basic protein induces IL-8 expression in human intestinal myofibroblasts.

Authors:  G T Furuta; S J Ackerman; J Varga; A M Spiess; M Y Wang; B K Wershil
Journal:  Clin Exp Immunol       Date:  2000-10       Impact factor: 4.330

2.  Targeting CAMKII to reprogram tumor-associated macrophages and inhibit tumor cells for cancer immunotherapy with an injectable hybrid peptide hydrogel.

Authors:  Xiaomeng Dai; Jingshu Meng; Suke Deng; Lingling Zhang; Chao Wan; Lisen Lu; Jing Huang; Yan Hu; Zhanjie Zhang; Yan Li; Jonathan F Lovell; Gang Wu; Kunyu Yang; Honglin Jin
Journal:  Theranostics       Date:  2020-02-10       Impact factor: 11.556

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.